Deteriorating beta-cell function in type 2 diabetes: A long-term model

QJM: An International Journal of Medicine

Volumn 96, Issue 4, 2003, Pages 281-288

  Bagust, A ^a   Beale, S ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL PRACTICE; CONTROLLED STUDY; DATA ANALYSIS; DIABETES CONTROL; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHESIS; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL RESEARCH; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONLINEAR SYSTEM; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

EID: 0037384206     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg040     Document Type: Article

References (25)

1. Matthews DR. Insulin resistance and β-cell function: a clinical perspective. Diabetes Obes Metab 2001; 3(Suppl. 1):S28-33.
2. Kahn SE. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86:4047-58.
3. Gerich JE. Addressing the insulin secretion defect: a logical first-line approach. Metabolism 2000; 49(10 Suppl. 2):12-16.
4. Poitout V, Robertson RP. An integrated view of β-cell dysfunction in type-II diabetes. Ann Rev Med 1996; 47:69-83.
5. Kahn SE. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108(Suppl. 6a):2-8S.
6. Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, Pockaj B, Turner RC. Natural history of pancreatic islet β-cell function in type 2 diabetes mellitus studies over six years by homeostasis model assessment. Diabet Med 1988; 5:36-41.
7. UKPDS Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995; 44:1249-58.
8. Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Diabetes Metab 1996; 22:185-91.
9. Ostgren CJ, Lindblad U, Ranstam J, Melander A, Ranstam L. Glycaemic control, disease duration and β-cell function in a Swedish community: Skaraborg hypertension and diabetes project. Diabetic Medicine 2002; 19:125-9.
10. UKPDS Study Group. UK Prospective Diabetes Study V. Characterisitics of newly presenting type 2 diabetic patients: estimated insulin sensitivity and islet β-cell function. Diabet Med 1988; 5:444-8.
11. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, Manninen D, Garfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997; 20:725-34.
12. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycaemia. Diabetes Care 1997; 20:735-44.
13. Brown JB, Russell A, Chan W, Pedula K, Aickin M. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000; 50(Suppl. 3):S15-46.
14. Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, Wenzel H. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000; 50(Suppl. 3):S47-56.
15. Bagust A, Hopkinson PK, Maier W, Currie CJ. An economic model of the long-term health care burden of type II diabetes. Diabetologia 2001; 44:2140-55.
16. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10 year follow-up of the Belfast Diet Study. Diabet Med 1998; 15:290-6.
17. Hadden DR, Blair ALT, Wilson EA, Boyle DM, Atkinson AB, Kennedy AL, Buchanan KD, Merrett JD, Montgomery DA, Weaver JA. Natural history of diabetes presenting age 40-69 years: a prospective study of the influence of intensive dietary therapy. Q J Med 1986; 59:579-98.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-19.
19. Levy JC, Matthews DR, Hermans MP. Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program (letter). Diabetes Care 1998; 21:2191-2.
20. Topp B, Promislow K, de Vries G, Miura RM, Finegood DT. A model of β-cell mass, insulin and glucose kinetics: pathways to diabetes. J Theor Biol 2000; 206:605-19.
21. Chiu KC, Lee NP, Cohan P, Chuang LM. Beta cell function declines with age in glucose tolerant Caucasians. Clin Endocrinol (Oxf) 2000; 53:569-75.
22. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51:2796-803.
23. Lyons TJ, Kennedy L, Atkinson AB, Buchanan KD, Hadden DR, Weaver JA. Predicting the need for insulin therapy in late onset (40-69 years) diabetes mellitus. Diabet Med 1984; 1:105-7.
24. Taverna MJ, Pacher N, Bruzzo F, Slama G, Selam JL. Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in type 2 diabetes. Diabet Med 2001; 18:584-8.
25. Harris IH, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815-19.